Apellis Pharmaceuticals (NASDAQ:APLS) Receives “Market Perform” Rating from Raymond James Financial

Apellis Pharmaceuticals (NASDAQ:APLS)‘s stock had its “market perform” rating reaffirmed by Raymond James Financial in a research report issued on Wednesday,Benzinga reports.

A number of other research firms have also recently issued reports on APLS. Royal Bank Of Canada cut their price target on Apellis Pharmaceuticals from $22.00 to $21.00 and set a “sector perform” rating for the company in a report on Wednesday, February 25th. Wall Street Zen cut shares of Apellis Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Saturday, February 28th. Bank of America raised shares of Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Wednesday, January 21st. Wedbush reduced their target price on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Finally, Stifel Nicolaus decreased their price target on shares of Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, December 19th. Nine investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $31.89.

Apellis Pharmaceuticals Price Performance

NASDAQ APLS traded up $0.17 during trading hours on Wednesday, reaching $40.40. 12,273,116 shares of the company’s stock were exchanged, compared to its average volume of 4,373,854. The firm has a fifty day moving average of $21.11 and a 200-day moving average of $22.58. Apellis Pharmaceuticals has a one year low of $16.10 and a one year high of $40.45. The stock has a market cap of $5.16 billion, a PE ratio of 310.75 and a beta of 0.26. The company has a current ratio of 3.14, a quick ratio of 2.70 and a debt-to-equity ratio of 0.98.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.86. The firm had revenue of $199.91 million during the quarter, compared to the consensus estimate of $199.28 million. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The business’s revenue for the quarter was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.29) EPS. On average, equities research analysts predict that Apellis Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 27,192 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $591,969.84. Following the completion of the sale, the chief executive officer directly owned 286,045 shares of the company’s stock, valued at approximately $6,227,199.65. The trade was a 8.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mark Jeffrey Delong sold 3,371 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $73,386.67. Following the transaction, the insider owned 78,353 shares in the company, valued at approximately $1,705,744.81. The trade was a 4.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 115,537 shares of company stock valued at $2,486,082. 6.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Large investors have recently bought and sold shares of the business. Jones Financial Companies Lllp boosted its stake in Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after acquiring an additional 1,373 shares during the last quarter. Allworth Financial LP raised its position in shares of Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after acquiring an additional 857 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of Apellis Pharmaceuticals by 141.2% in the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after purchasing an additional 1,570 shares during the period. Quantbot Technologies LP acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $64,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 338.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after purchasing an additional 4,191 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Biogen agreed to acquire Apellis for $41.00 in cash per share plus a CVR that could add up to $4 per share on SYFOVRE sales milestones — the deal is the primary catalyst for the sharp rise in APLS shares. Biogen to buy Apellis Pharmaceuticals for $5.6 billion
• Neutral Sentiment: Broker reaction: HC Wainwright reaffirmed a “neutral” rating and set a $41 price target (down from $48), which implies little upside versus the acquisition price and signals mixed analyst guidance post‑deal. HC Wainwright rating note
• Neutral Sentiment: Zacks notes that despite heavy volume and the deal news, recent trends in earnings estimate revisions could limit sustainable upside unless fundamentals or deal certainty improve. Apellis Moves 135.4% Higher: Will This Strength Last?
• Negative Sentiment: Multiple shareholder law firms announced investigations (Kahn Swick & Foti, Halper Sadeh, Ademi LLP) questioning whether Apellis shareholders are receiving a fair price/process in the sale — potential legal challenges or disclosure fights could delay closing or add deal uncertainty. KSF investor alert
• Negative Sentiment: Analyst downgrades and target cuts around the deal: Needham cut APLS from “buy” to “hold” and Cantor Fitzgerald trimmed its target previously — these actions reflect mixed views on deal premium and post‑close expectations. Cantor Fitzgerald cuts PT on Apellis

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.